{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:41Z","timestamp":1793978861486,"version":"4.8.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119295","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:53:19Z","timestamp":1788533599000},"page":"119295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting the myeloid immune checkpoint ILT3 (LILRB4) with small molecules enables reprogramming of suppressive tumor immunity"],"prefix":"10.1016","volume":"319","author":[{"given":"Somaya A.","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Monari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Miclot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Barbault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-3331","authenticated-orcid":false,"given":"Moustafa T.","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119295_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119295_bib2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119295_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2026.119295_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejmech.2026.119295_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119295_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119295_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2026.119295_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2026.119295_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejmech.2026.119295_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119295_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"Cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119295_bib12","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119295_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejmech.2026.119295_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2015.07.006","article-title":"RORC1 regulates tumor-promoting emergency granulo-monocytopoiesis","volume":"28","author":"Strauss","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119295_bib15","doi-asserted-by":"crossref","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"21","key":"10.1016\/j.ejmech.2026.119295_bib16","doi-asserted-by":"crossref","first-page":"18013","DOI":"10.1074\/jbc.M111.221028","article-title":"Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3\/LIR-5\/CD85k)","volume":"286","author":"Cheng","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119295_bib17","article-title":"Leukocyte immunoglobulin-like receptor B4: a keystone in immune modulation and therapeutic target in cancer and beyond","volume":"3","author":"Lu","year":"2024","journal-title":"Cancer Innov"},{"key":"10.1016\/j.ejmech.2026.119295_bib18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119295_bib19","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.4049\/jimmunol.1100274","article-title":"Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer","volume":"186","author":"Krempski","year":"2011","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119295_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5114\/ceji.2023.125238","article-title":"Molecular regulatory mechanism of LILRB4 in the immune response","volume":"48","author":"Liu","year":"2023","journal-title":"Cent. Eur. J. Immunol."},{"key":"10.1016\/j.ejmech.2026.119295_bib21","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.4049\/jimmunol.178.11.7432","article-title":"Soluble Ig-like transcript 3 inhibits tumor alloreactivity and generates CD8+ suppressor T cells","volume":"178","author":"Suciu-Foca","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2026.119295_bib22","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1172\/JCI97570","article-title":"Blocking immunoinhibitory receptor LILRB4 on antigen-presenting cells enhances antitumor immunity","volume":"128","author":"Chen","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.119295_bib23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41556-019-0298-1","article-title":"Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response","volume":"21","author":"Salvagno","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119295_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/BS9.0000000000000109","article-title":"LILRB4, an immune checkpoint on myeloid cells","volume":"4","author":"Yang","year":"2022","journal-title":"Blood Sci"},{"key":"10.1016\/j.ejmech.2026.119295_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jlb.66.3.375","article-title":"A novel family of inhibitory receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells","volume":"66","author":"Colonna","year":"1999","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejmech.2026.119295_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.0001-2815.2004.00290.x","article-title":"The LILR family: modulators of innate and adaptive immune pathways in health and disease","volume":"64","author":"Brown","year":"2004","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ejmech.2026.119295_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1282874","article-title":"Human leukocyte immunoglobulin-like receptors in health and disease","volume":"14","author":"Redondo-Garc\u00eda","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119295_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40364-024-00705-7","article-title":"The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications","volume":"12","author":"Hodges","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ejmech.2026.119295_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118253","article-title":"The immune checkpoint LILRB4 promotes immune evasion and is correlated with disease progression and secondary malignancies in chronic lymphocytic leukemia","volume":"189","author":"Sordo-Bahamonde","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119295_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiaf052","article-title":"Presence of LILRB4 SNP rs1048801 modulates acute myeloid leukemia progression and inhibits CD4+ T cells proliferation","volume":"117","author":"Zhou","year":"2025","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119295_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100126","article-title":"A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia","volume":"2","author":"Aribi","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119295_bib32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/intimm\/dxab028","article-title":"Blockade of checkpoint ILT3\/LILRB4\/gp49B binding to fibronectin ameliorates autoimmune disease in BXSB\/Yaa mice","volume":"33","author":"Su","year":"2021","journal-title":"Int. Immunol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119295_bib33","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1158\/1535-7163.MCT-20-0407","article-title":"LILRB4-targeting antibody-drug conjugates for the treatment of acute myeloid leukemia","volume":"19","author":"Anami","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119295_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.752065","article-title":"Small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy: mechanisms of action and other considerations for their advanced development","volume":"13","author":"Sasikumar","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119295_bib35","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.7150\/thno.130935","article-title":"Small molecules targeting the PD-1\/PD-L1 axis for cancer immunotherapy","volume":"16","author":"Yin","year":"2026","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119295_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500972","article-title":"Research progress and clinical translation challenges of small-molecule inhibitors targeting PD-L1","volume":"21","author":"Qian","year":"2026","journal-title":"ChemMedChem"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119295_bib37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acsmedchemlett.3c00054","article-title":"Discovery of first-in-class small molecule inhibitors of lymphocyte activation gene 3 (LAG-3)","volume":"14","author":"Abdel-Rahman","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119295_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.slasd.2023.04.003","article-title":"Development of a high-throughput TR-FRET screening assay for LAG-3\/FGL1 interaction","volume":"28","author":"Abdel-Rahman","year":"2023","journal-title":"SLAS Discov"},{"issue":"11","key":"10.1016\/j.ejmech.2026.119295_bib39","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1021\/acsmedchemlett.4c00350","article-title":"From virtual screens to cellular target engagement: new small molecule ligands for the immune checkpoint LAG-3","volume":"15","author":"Fuchs","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"42","key":"10.1016\/j.ejmech.2026.119295_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq5540","article-title":"Small molecules from antibody pharmacophores (SMAbPs) as a hit identification workflow for immune checkpoints","volume":"10","author":"Abdel-Rahman","year":"2024","journal-title":"Sci. Adv."},{"issue":"16","key":"10.1016\/j.ejmech.2026.119295_bib41","doi-asserted-by":"crossref","first-page":"11464","DOI":"10.1021\/acs.jmedchem.3c00960","article-title":"Discovery of small-molecule TIM-3 inhibitors for acute myeloid leukemia using pharmacophore-based virtual screening","volume":"66","author":"Abdel-Rahman","year":"2023","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119295_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300305","article-title":"Discovery of ICOS-targeted small molecules using pharmacophore-based screening","volume":"18","author":"Calvo-Barreiro","year":"2023","journal-title":"ChemMedChem"},{"issue":"9","key":"10.1016\/j.ejmech.2026.119295_bib43","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1039\/D3MD00150D","article-title":"First-in-class small molecule inhibitors of ICOS\/ICOSL interaction as a novel class of immunomodulators","volume":"14","author":"Abdel-Rahman","year":"2023","journal-title":"RSC Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2026.119295_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400545","article-title":"Discovery of ICOS-targeted small molecules using affinity selection mass spectrometry screening","volume":"19","author":"Zhang","year":"2024","journal-title":"ChemMedChem"},{"issue":"38","key":"10.1016\/j.ejmech.2026.119295_bib45","doi-asserted-by":"crossref","first-page":"16194","DOI":"10.1021\/jacs.0c07276","article-title":"Discovery and optimization of small-molecule ligands for V-Domain Ig suppressor of T-Cell activation (VISTA)","volume":"142","author":"Gabr","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"30","key":"10.1016\/j.ejmech.2026.119295_bib46","doi-asserted-by":"crossref","first-page":"26837","DOI":"10.1021\/acsomega.3c01462","article-title":"Design, synthesis, ADME, and anticancer studies of newer N-Aryl-5-(3,4,5-Trifluorophenyl)-1,3,4-Oxadiazol-2-Amines: an insight into experimental and theoretical investigations","volume":"8","author":"Agarwal","year":"2023","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119295_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1758-2946-4-17","article-title":"An advanced semantic chemical editor, visualization, and analysis platform","volume":"4","author":"Hanwell","year":"2012","journal-title":"J. Cheminf."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119295_bib48","doi-asserted-by":"crossref","first-page":"18013","DOI":"10.1074\/jbc.M111.221028","article-title":"Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3\/LIR-5\/CD85k): a myeloid inhibitory receptor involved in immune tolerance","volume":"286","author":"Cheng","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2026.119295_bib49","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119295_bib50","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1016\/j.ejmech.2009.03.028","article-title":"Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 Gp120 entry inhibitors","volume":"44","author":"Teixeira","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119295_bib51","series-title":"Amber 2025","author":"Case","year":"2025"},{"issue":"16","key":"10.1016\/j.ejmech.2026.119295_bib52","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"J. Comput. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119295_bib53","doi-asserted-by":"crossref","DOI":"10.1063\/5.0019056","article-title":"A fast and high-quality charge model for the next generation general AMBER force field","volume":"153","author":"He","year":"2020","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2026.119295_bib54","unstructured":"Jakalian, A.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC Model: II. Parameterization and Validation."},{"issue":"16","key":"10.1016\/j.ejmech.2026.119295_bib55","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jcc.10128","article-title":"Fast, efficient generation of high\u2010quality atomic charges. AM1\u2010BCC model: II. Parameterization and validation","volume":"23","author":"Jakalian","year":"2002","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119295_bib56","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","article-title":"ff19SB: amino-acid specific protein backbone parameters trained against quantum mechanics energy surfaces in solution","volume":"16","author":"Tian","year":"2020","journal-title":"J. Chem. Theor. Comput."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119295_bib57","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/(SICI)1096-987X(19980730)19:10<1179::AID-JCC6>3.0.CO;2-J","article-title":"Temperature dependence of TIP3P, SPC, and TIP4P water from NPT Monte Carlo simulations: seeking temperatures of maximum density","volume":"19","author":"Jorgensen","year":"1998","journal-title":"J. Comput. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119295_bib58","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theor. Comput."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119295_bib59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"Visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119295_bib60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.str.2005.01.006","article-title":"Software extensions to UCSF chimera for interactive visualization of large molecular assemblies","volume":"13","author":"Goddard","year":"2005","journal-title":"Structure"},{"issue":"16","key":"10.1016\/j.ejmech.2026.119295_bib61","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-Point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:01:46Z","timestamp":1793977306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":61,"alternative-id":["S0223523426007403"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119295","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the myeloid immune checkpoint ILT3 (LILRB4) with small molecules enables reprogramming of suppressive tumor immunity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119295"}}